| Document |
Document Title |
|
WO/2023/288109A1 |
Provided herein is the design and synthesis of novel molecular rotor fluorophores of formula I useful for detection of amyloid or amyloid like proteins. The fluorophores are designed to exhibit enhanced fluorescence emission upon associa...
|
|
WO/2023/283586A2 |
Probenecid prodrug compounds, and formulations including one or more of probenecid, metabolites and analogs thereof, and prodrugs thereof, and pharmaceutically acceptable salt thereof are provided. Delivery vehicles and pharmaceutical co...
|
|
WO/2023/277605A1 |
The present invention provides a novel compound for a capping layer and an organic light-emitting device containing same.
|
|
WO/2023/277593A1 |
The present invention provides a novel compound for a capping layer, and an organic light-emitting device comprising same.
|
|
WO/2023/274037A1 |
Disclosed in the present invention are a method and system for purifying NMMO and the obtained NMMO hydrate crystal. The purification method is suitable for purifying NMMO in a cellulose product coagulating bath, and by means of the meth...
|
|
WO/2023/274258A1 |
Provided are a heteroatom-substituted aromatic compound, and a preparation method therefor and the use thereof, which belong to the field of medicinal chemistry. The compound is a compound as represented by formula I, or a salt, a stereo...
|
|
WO/2023/274038A1 |
Disclosed are a purification method and system for N-methylmorpholine-N-oxide (NMMO), and obtained NMMO. The present invention is used for recovering and purifying NMMO in a lyocell fiber coagulation bath. The method comprises: subjectin...
|
|
WO/2022/269251A1 |
The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: (I) wherein RA, RB, RC and RD are as defined herein.
|
|
WO/2022/264471A1 |
Provided is a method of catalytic hydrogenation and reduction with which a catalytic hydrogenation and reduction reaction can be performed at a high inversion rate. A method of catalytic hydrogenation and reduction in which a reactive su...
|
|
WO/2022/262350A1 |
The present invention relates to the field of pharmaceutical chemistry, specifically to a class of substituted diaryl compounds of formula (I), and a preparation method therefor, a pharmaceutical preparation containing same, and the medi...
|
|
WO/2022/254248A1 |
The present invention provides a method for preparation of 1-(2-((2,4-Dimethylphenyl)thio)phenyl)piperazine and its salts through a novel intermediate,2-((2,4-dimethylphenyl)thio)-N-hydroxybenzamide
. The method involves mild conditions,...
|
|
WO/2022/253959A1 |
The present invention relates to compounds, pharmaceutical compositions and medicaments suitable for use in the prevention and/or treatment of neurodegenerative disorders, such as for example demyelinating diseases. These compounds have ...
|
|
WO/2022/247755A1 |
Provided herein are lipid compounds that can be used in combination with other lipid components, such as neutral lipids, cholesterol andpolymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucl...
|
|
WO/2022/249789A1 |
The present invention provides a novel hole transport material which is dopant-free for the purpose of stability improvement and still enables a perovskite solar cell to achieve a sufficient photoelectric conversion efficiency and high d...
|
|
WO/2022/246929A1 |
The present invention relates to the technical field of drug synthesis, and provides a preparation method for an ABT-737 key intermediate and a preparation method for ABT-737. A compound having a structure as represented by formula I is ...
|
|
WO/2022/245124A1 |
The present invention relates to an ethene compound in a novel structure, a pharmaceutically acceptable salt thereof, or an N-oxide thereof, which each act as an estrogen-related receptor β/γ (ERRβ/γ) inverse agonist, and a pharmaceu...
|
|
WO/2022/246116A2 |
Provided herein are antibody-based antiviruses comprising a fusion protein that comprises a transmembrane polypeptide and an antibody which binds to a surface protein of a virus. Further provided herein are antibody-based antiviruses for...
|
|
WO/2022/242424A1 |
Disclosed are a purification method, system and detection method for N-methylmorpholine N-oxide (NMMO) and an obtained NMMO. The NMMO is derived from a crude product of NMMO prepared by reacting N-methylmorpholine with hydrogen peroxide....
|
|
WO/2022/245627A1 |
In one aspect, the application relates to sulfonyl chalcogenide urea derivatives of Formula II, including sulfonyl thioureas and sulfonyl selenoureas, and methods of making the same, wherein the methods can be carried out under mild cond...
|
|
WO/2022/240992A1 |
Described herein are TRPML1inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of TRPML1-mediated disorders or diseases.
|
|
WO/2022/237903A1 |
Provided are a quinazoline compound and an application thereof. Specifically provided is a quinazoline compound as shown in formula I. The compound is novel in structure and has a good inhibitory effect on cell factors TNF-α, IL-6, and ...
|
|
WO/2022/240277A1 |
The invention relates to novel compounds of formulae (I) and (II), to the use thereof as a drug, particularly for the treatment of SARS-CoV-2, for the treatment of COVID-19 disease and any diseases related to beta-coronaviruses, and for ...
|
|
WO/2022/236133A1 |
Provided herein are fatty acid amide (FAAH) cleavable prodrugs of thyromimetics and pharmaceutical compositions comprising these compounds with at least one pharmaceutically acceptable excipient further comprising a peripherally restrict...
|
|
WO/2022/230354A1 |
The purpose of the present invention is to provide a compound that can be suitably used in a fluorochrome or similar, a novel fluorochrome and kit for conveniently detecting cells, and a novel method for conveniently detecting cells or s...
|
|
WO/2022/232518A1 |
A pharmaceutical composition includes calxinin formulated for treating a viral infection. The pharmaceutical composition may be used to treat a subject having, or at risk of having, a viral infection. In some embodiments, the viral infec...
|
|
WO/2022/227743A1 |
The present invention relates to the technical field of medicines, and provides a memantine urea derivative, a preparation method therefore, and an application thereof. The memantine urea derivative provided by the present invention has ...
|
|
WO/2022/218348A1 |
This invention provides a new synthesis method of lactam compounds, which is characterized in that, the method uses sodium chlorite as an oxidant, and under the catalysis of carbon dioxide, oxidizes cyclic amine compounds to lactam compo...
|
|
WO/2022/221688A1 |
The present invention provides, among other things, a novel class of cationic lipid compounds (e.g., cationic lipids having a structure according to Formula (I)) for in vivo delivery of therapeutic agents, such as nucleic acids. It is co...
|
|
WO/2022/214137A1 |
The invention relates to a chemical compound of the general formula (I), to the use of such a chemical compound in an electronic component, and an electronic component comprising such a chemical compound.
|
|
WO/2022/213200A1 |
The present invention relates to a process preparing and therapeutic use of endocannabinoid-targeting prodrugs in a delivery system. In particular, the present invention relates to prodrugs of the endocannabinoid system- targeting molecu...
|
|
WO/2022/213198A1 |
There are provided Tissue Transglutaminase (TG2) inhibitor compounds, and compositions and methods of use thereof for the prevention or treatment of a disease state mediated by TG2, such as a cancer, a neurodegenerative disease such as H...
|
|
WO/2022/208545A1 |
The present invention discloses a process for the hydrogenation of imines of Formula I by palladium-based catalyst to provide product of Formula II with more than 95% conversion of substrate and more than 95% of desired hydrogenated prod...
|
|
WO/2022/204080A1 |
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions con...
|
|
WO/2022/204046A1 |
Substituted naphthyl p38α mitogen-activated protein kinase inhibitors, pharmaceutical compositions thereof, and the use of the substituted naphthyl p38α mitogen-activated protein kinase inhibitors and pharmaceutical compositions thereo...
|
|
WO/2022/197798A1 |
Provided herein are methods and compositions for the treatment of diseases of ACTH excess, such as Cushing's disease, ectopic ACTH syndrome, and congenital adrenal hyperplasia.
|
|
WO/2022/190047A1 |
The present invention relates to a novel alternating diameter flow reactor for continuous - flow reactions, a system for continuous-flow reactions (as shown in Figure 1) comprising said alternating diameter flow reactor, a method for the...
|
|
WO/2022/189810A1 |
This invention relates to compounds that can be used to treat viral infections. The compounds are papain-like protease (PLpro) inhibitors.
|
|
WO/2022/192562A1 |
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of USP30, and the treatment of USP30-mediated disorders.
|
|
WO/2022/189636A1 |
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, or isomer thereof. The invention also provides pharmaceutical compositions comprising the compounds of formula (I) as well as their ...
|
|
WO/2022/192162A1 |
Pharmaceutical compositions of the invention comprise heteroaromatic compounds having a disease-modifying action in the treatment of fungal infections and diseases associated with fungal infection.
|
|
WO/2022/187206A1 |
Disclosed herein are novel dual-target compounds that bind at both the mu-opioid receptor (MOR) and dopamine D3 receptors (D3R) to provide MOR-mediated analgesia, while minimizing addictive liability through D3R antagonism/partial agonis...
|
|
WO/2022/186162A1 |
The purpose of the present invention is to provide a method for producing a nucleophilic reaction product, the method being capable of using a halogenated carbonyl compound for the reaction without requiring isolation thereof, while bein...
|
|
WO/2022/185227A1 |
The present invention relates to novel Formyl Peptide Receptor subtype 2 (FPR2) agonist compounds and their use in the recovery of the inflammatory phenomena in which said receptor is involved, particularly in the context of the treatmen...
|
|
WO/2022/178228A1 |
The invention provides arylthioether acetamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as bacterial infections, and in inhibiting LpxA activity.
|
|
WO/2022/174525A1 |
The present invention relates to the fields of medicinal chemistry and pharmacotherapeutics, and in particular to a compound, a preparation method therefor and a use thereof, relating to the technical field of pharmacy. Provided are a co...
|
|
WO/2022/170834A1 |
Disclosed in the present invention is the use of an ionizable cationic lipid analog material as a protein drug delivery carrier. The cationic lipid analog material of the present invention has an efficient capability of intracellular del...
|
|
WO/2022/170835A1 |
Disclosed in the present invention is the application of an ionizable cationic lipid analogue material as a nucleic acid drug delivery vector or a transfection reagent. The cationic lipid analogue material of the present invention can ef...
|
|
WO/2022/168884A1 |
The present invention provides a novel cationic lipid having excellent encapsulation and delivery stability of nucleic acid medicines. Provided is a compound represented by formula (I) or a pharmacologically acceptable salt thereof. (In ...
|
|
WO/2022/166994A1 |
Provided in the present invention are a naphthyl urea compound, a preparation method therefor and the use thereof. A naphthyl urea parent nucleus group with a biological activity contained in the naphthyl urea compound is further chemica...
|
|
WO/2022/163209A1 |
A carbon dioxide absorber which comprises an amine compound (A) having a heterocyclic structure (X) selected from among oxygen-containing heterocyclic structures and sulfur-containing heterocyclic structures and which has a content of th...
|
